Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...

A holistic or integrative approach to hair loss considers the hair growth cycle and hair loss from a nutritional, ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Regeneron and Alnylam are to research treatments ... Alnylam filed its first RNAi therapy with the FDA last month, asking the regulator to review patisiran for the rare disease Hereditary ATTR ...

AZ and Regeneron will collaborate on finding small ... using an acquired priority voucher to speed up the review time. Looming on the horizon is Lilly's tirzepatide, which has posted impressive ...

29 August 2024 Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the ...

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...

While marketers know that an omnichannel approach can deliver a more seamless brand experience, many pharma companies are still in the early stages of implementing fully integrated omnichannel ...

Burnout among physicians and residents continues to grow, with six out of 10 reporting these feelings, along with continued ...